Victoria Socha

DocwireNews

Resistant hypertension is prevalent among patients with advanced chronic kidney disease (CKD), and is associated with an increased likelihood of poor cardiovascular and renal outcomes. However, according to Bertram Pitt, MD, and colleagues, patients with advanced CKD are often not treated for resistant hypertension due to concerns regarding side effects, primarily <a href="https://www.docwirenews.com/nephtimes/nephtimes-diseases-and-conditions/hyperkalemia/dyskalemias-and-short-term-healthcare-use-in-patients-with-advanced-ckd/">hyperkalemia</a>, associated with the currently available recommended add-on therapy, steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone. KBP-5074 is a novel non-steroidal MRA that can treat resistant hypertension in patients with reduced kidney function without the risk of hyperkalemia.In the journal Expert Opinion on Investigational Drugs [<a href="https://doi.org/10.1080/13543784.2021.1985462">doi.org/10.1080/13543784.2021.1985462</a>], the researchers provide a review of the current state of treatment for resistant hypertension in patients with stage 3B/4 CKD as it relates to available steroidal MRAs. The review also describes emerging data on nonsteroidal MRAs, including KBP-5074.The review notes that in a randomized, double-blind, placebo-controlled phase 2b trial, KBP-5074 &ldquo;demonstrated clinical efficacy and safety in treating resistant hypertension in stage 3B/4 CKD and offers a potential new treatment option in this population at high risk for cardiovascular disease and CKD progression.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Avoiding Hyperkalemia Associated with Treatment of Resistant Hypertension

Hyperkalemia

Resistant hypertension is prevalent among patients with advanced chronic kidney disease (CKD), and is associated with an increased likelihood of poor cardiovascular and renal ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe